Chan D W, Miao Y C
Clin Chem. 1986 Dec;32(12):2143-6.
This is an affinity chromatographic procedure for separating variants of alpha-fetoprotein in 0.1 mL of serum on a disposable mini-column containing 0.9 mL of concanavalin A-Sepharose, at pH 6.4 and with a flow rate of 5 mL/h. The binding capacity of the column is 52 micrograms. Analytical recovery was 90%. Between-run CVs varied from 2.0% for samples with a high percentage of concanavalin A nonreactive fraction to 13% for samples with a low percentage. The mean proportion of nonreactive alpha-fetoprotein was 13.4% for patients with hepatocellular carcinoma, 62.2% for testicular carcinoma, and 8.9% for nonmalignant liver diseases. This suggests that the alpha-fetoprotein variants could be used to distinguish hepatocellular carcinoma from other carcinomas. Serial determination of the concanavalin A nonreactive fraction in such patients showed a relatively constant percentage. This indicates that monitoring variants in patients with hepatocellular carcinoma throughout their clinical course may not provide useful information additional to that provided by the values for total serum alpha-fetoprotein.
这是一种亲和色谱法，用于在含有0.9 mL伴刀豆球蛋白A - 琼脂糖的一次性微型柱上，于pH 6.4、流速为5 mL/h的条件下，分离0.1 mL血清中的甲胎蛋白变体。该柱的结合容量为52微克。分析回收率为90%。批间变异系数在伴刀豆球蛋白A非反应性部分比例高的样品中为2.0%，在比例低的样品中为13%。肝细胞癌患者非反应性甲胎蛋白的平均比例为13.4%，睾丸癌患者为62.2%，非恶性肝病患者为8.9%。这表明甲胎蛋白变体可用于区分肝细胞癌与其他癌症。对此类患者连续测定伴刀豆球蛋白A非反应性部分显示出相对恒定的百分比。这表明在肝细胞癌患者的整个临床过程中监测变体，可能无法提供比血清总甲胎蛋白值更多的有用信息。
